Autologous CIK and DC Combined with Sorafenib in The Treatment of Patients with Advanced Hepatocellular Carcinoma: A Clinical Observation

Objective To analyze the clinical efficacy and side effects in patients with advanced hepatic cancer treated with Sorafenib and autologous CIK and CD.Methods Cytokine-induced killer cells(cytokine induced killer,CIK) and dendritic cells(Dendritic Cell,DC) from the peripheral blood of the patients with advanced hepatocellular carcinoma were amplified.The amplified CIK and DC-CIK were transfused back,and Sorafenib was given to the patients,after the phenotype of CIK and DC-CIK was tested by using the flow cytometry.Results After one course of treatment,0 of the 44 patients had CR,and 15,22,5,and 2 of the 44 patients had PR,MR,SD,and PD disease,with a total remission rate(CR+PR+MR) of 84.1%.Sorafenib and autologous transfusion of CIK and CD improved the immune function and quality of life.Conclusion Autologous CIK and DC transfusion combined with Sorafenib may have good efficacy with accepted toxicities.